Tomomi Kimura

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6508236/publications.pdf

Version: 2024-02-01

1039406 839053 18 313 9 18 citations h-index g-index papers 18 18 18 486 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	The Asian Pharmacoepidemiology Network (AsPEN): promoting multiâ€national collaboration for pharmacoepidemiologic research in Asia. Pharmacoepidemiology and Drug Safety, 2013, 22, 700-704.	0.9	61
2	Multiâ€country rapid adverse drug event assessment: the Asian Pharmacoepidemiology Network (AsPEN) antipsychotic and acute hyperglycaemia study. Pharmacoepidemiology and Drug Safety, 2013, 22, 915-924.	0.9	45
3	The Epidemiology of Clostridium difficile Infection in Japan: A Systematic Review. Infectious Diseases and Therapy, 2018, 7, 39-70.	1.8	40
4	Proton pump inhibitors and risk of <i>Clostridium difficile </i> infection: a multi-country study using sequence symmetry analysis. Expert Opinion on Drug Safety, 2016, 15, 1589-1595.	1.0	36
5	Pharmacovigilance systems and databases in Korea, Japan, and Taiwan. Pharmacoepidemiology and Drug Safety, 2011, 20, 1237-1245.	0.9	34
6	Characterization and risk factors for recurrence of Clostridioides (Clostridium) difficile infection in Japan: A nationwide real-world analysis using a large hospital-based administrative dataset. Journal of Infection and Chemotherapy, 2019, 25, 615-620.	0.8	14
7	Validation and Recalibration of Charlson and Elixhauser Comorbidity Indices Based on Data From a Japanese Insurance Claims Database. Japanese Journal of Pharmacoepidemiology/Yakuzai Ekigaku, 2019, 24, 53-64.	0.0	14
8	Characteristics of Patients with Diabetes Initiating Sodium Glucose Co-transporter-2 Inhibitors (SGLT2i): Real-World Results from Three Administrative Databases in Japan. Diabetes Therapy, 2019, 10, 549-562.	1.2	10
9	Excess length of hospital stay, mortality and cost attributable to <i>Clostridioides</i> (<i>Clostridium</i>) <i>difficile</i> infection and recurrence: a nationwide analysis in Japan. Epidemiology and Infection, 2020, 148, e65.	1.0	10
10	Diagnosis Patterns of CKD and Anemia in the Japanese Population. Kidney International Reports, 2020, 5, 694-705.	0.4	8
11	Clostridioides (Clostridium) difficile infection in Japanese hospitals 2008–2017: A real-world nationwide analysis of treatment pattern, incidence and testing density. Journal of Infection and Chemotherapy, 2020, 26, 438-443.	0.8	7
12	Validation and Recalibration of Charlson and Elixhauser Comorbidity Indices to Predict In-hospital Mortality in Hospitalized Patients in a Japanese Hospital-Based Administrative Database. Japanese Journal of Pharmacoepidemiology/Yakuzai Ekigaku, 2020, 25, 1-14.	0.0	6
13	Drug Utilization Patterns in Patients with Diabetes Initiating Sodium Glucose Co-Transporter-2 Inhibitors (SGLT2i) in Japan: A Multi-Database Study (2014–2017). Diabetes Therapy, 2019, 10, 2233-2249.	1.2	5
14	Real-World Effectiveness of Sodium Glucose Co-Transporter-2 Inhibitors in Japanese Patients with Diabetes Mellitus. Diabetes Therapy, 2019, 10, 2219-2231.	1.2	5
15	Passive surveillance of rotavirus gastroenteritis-associated hospitalization using nationwide administrative databases in Japan. Journal of Infection and Chemotherapy, 2019, 25, 175-181.	0.8	5
16	Suitability of databases in the <scp>Asiaâ€Pacific</scp> for collaborative monitoring of vaccine safety. Pharmacoepidemiology and Drug Safety, 2021, 30, 843-857.	0.9	5
17	Switching from intravenous to oral antibiotics in hospitalized patients with community-acquired pneumonia: A real-world analysis 2010–2018. Journal of Infection and Chemotherapy, 2020, 26, 706-714.	0.8	4
18	Estimating the causal effect of transient anemia status on renal and cardiovascular outcomes in community-dwelling patients in Japan at the beginning of impaired renal function using marginal structural modeling. Clinical and Experimental Nephrology, 2022, 26, 178-189.	0.7	4